All Articles
In this episode, we sit down with Jennifer R. Brown, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, to unpack the AMPLIFY trial that is reshaping chronic lymphocytic leukemia (CLL) treatment. She explains how this new oral combination isn’t just effective but patient-friendly, cutting down on complexity and paving the way for more accessible care. Tune in to hear how this breakthrough is setting the stage for the future of CLL therapy. Read More ›
Episode 1
Self-insured employers are understandably concerned about the costs of pharmacy benefits for their employees. Read More ›
For so many people, healthcare doesn’t begin in an exam room—it begins with anxiety. Read More ›
The financial aspect of cancer care deeply affects the patient’s experience economically, physically, and psychologically. Read More ›
This study investigates the implementation of social risk factor screening and referral processes in cancer survivorship care within 3 oncology settings in Washington, DC. Read More ›
On February 24, 2026, the FDA granted traditional approval to encorafenib (Braftovi) in combination with cetuximab and fluorouracil-based chemotherapy for the treatment of adults with metastatic colorectal cancer (CRC) harboring a BRAF V600E mutation, as determined by an FDA-authorized test. Read More ›
On February 19, 2026, the FDA approved the combination of acalabrutinib (Calquence) and venetoclax (Venclexta) for adult patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Read More ›
On March 5, 2026, the FDA approved teclistamab (Tecvayli) in combination with daratumumab hyaluronidase-fihj for adult patients with relapsed or refractory multiple myeloma who have received at least 1 prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. Read More ›
On February 26, 2026, the FDA granted accelerated approval to zongertinib (Hernexeos), a kinase inhibitor, for adults with unresectable or metastatic nonsquamous non–small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD)-activating mutations. Read More ›
On March 11, 2026, the FDA announced the launch of the FDA Adverse Event Monitoring System (AEMS), a unified platform designed to modernize and streamline the agency’s analysis of adverse event reports. Read More ›